Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 31
Filter
1.
eNeuro ; 10(12)2023 Dec.
Article in English | MEDLINE | ID: mdl-38053471

ABSTRACT

Alcohol use disorder (AUD) is a complex psychiatric disease characterized by periods of heavy drinking and periods of withdrawal. Chronic exposure to ethanol causes profound neuroadaptations in the extended amygdala, which cause allostatic changes promoting excessive drinking. The bed nucleus of the stria terminalis (BNST), a brain region involved in both excessive drinking and anxiety-like behavior, shows particularly high levels of pituitary adenylate cyclase-activating polypeptide (PACAP), a key mediator of the stress response. Recently, a role for PACAP in withdrawal-induced alcohol drinking and anxiety-like behavior in alcohol-dependent rats has been proposed; whether the PACAP system of the BNST is also recruited in other models of alcohol addiction and whether it is of local or nonlocal origin is currently unknown. Here, we show that PACAP immunoreactivity is increased selectively in the BNST of C57BL/6J mice exposed to a chronic, intermittent access to ethanol. While pituitary adenylate cyclase-activating polypeptide (PACAP) type 1 receptor-expressing cells were unchanged by chronic alcohol, the levels of a peptide closely related to PACAP, the calcitonin gene-related neuropeptide, were found to also be increased in the BNST. Finally, using a retrograde chemogenetic approach in PACAP-ires-Cre mice, we found that the inhibition of PACAP neuronal afferents to the BNST reduced heavy ethanol drinking. Our data suggest that the PACAP system of the BNST is recruited by chronic, voluntary alcohol drinking in mice and that nonlocally originating PACAP projections to the BNST regulate heavy alcohol intake, indicating that this system may represent a promising target for novel AUD therapies.


Subject(s)
Alcoholism , Septal Nuclei , Animals , Mice , Rats , Alcohol Drinking , Ethanol , Mice, Inbred C57BL , Pituitary Adenylate Cyclase-Activating Polypeptide/metabolism , Pituitary Adenylate Cyclase-Activating Polypeptide/pharmacology , Receptors, Pituitary Adenylate Cyclase-Activating Polypeptide/metabolism , Septal Nuclei/metabolism , Stress, Psychological
2.
Cell ; 186(18): 3845-3861.e24, 2023 08 31.
Article in English | MEDLINE | ID: mdl-37591240

ABSTRACT

Dopaminergic projections regulate various brain functions and are implicated in many neuropsychiatric disorders. There are two anatomically and functionally distinct dopaminergic projections connecting the midbrain to striatum: nigrostriatal, which controls movement, and mesolimbic, which regulates motivation. However, how these discrete dopaminergic synaptic connections are established is unknown. Through an unbiased search, we identify that two groups of antagonistic TGF-ß family members, bone morphogenetic protein (BMP)6/BMP2 and transforming growth factor (TGF)-ß2, regulate dopaminergic synapse development of nigrostriatal and mesolimbic neurons, respectively. Projection-preferential expression of their receptors contributes to specific synapse development. Downstream, Smad1 and Smad2 are specifically activated and required for dopaminergic synapse development and function in nigrostriatal vs. mesolimbic projections. Remarkably, Smad1 mutant mice show motor defects, whereas Smad2 mutant mice show lack of motivation. These results uncover the molecular logic underlying the proper establishment of functionally segregated dopaminergic synapses and may provide strategies to treat relevant, projection-specific disease symptoms by targeting specific BMPs/TGF-ß and/or Smads.


Subject(s)
Corpus Striatum , Dopamine , Animals , Mice , Mesencephalon , Motivation , Movement , Synapses
3.
Pharmacol Biochem Behav ; 230: 173605, 2023 09.
Article in English | MEDLINE | ID: mdl-37499765

ABSTRACT

BACKGROUND: Anxiety disorders are the most prevalent psychiatric disorders, and they are highly comorbid with chronic pain conditions. The central nucleus of the amygdala (CeA) is known not only for its role in the regulation of anxiety but also as an important site for the negative affective dimension of pain. Pituitary adenylate cyclase activating polypeptide (PACAP), a neuropeptide whose terminals are abundant in the CeA, is strongly implicated in the stress response as well as in pain processing. Here, using Cre-dependent viral vectors, we explored in greater detail the role of the PACAP projection to the CeA that originates in the lateral parabrachial nucleus (LPB). METHODS: We first performed a circuit mapping experiment by injecting an anterograde Cre-dependent virus expressing a fluorescent reporter in the LPB of PACAP-Cre mice and observing their projections. Then, we used a chemogenetic approach (a Cre-dependent Designer Receptors Activated by Designer Drugs, DREADDs) to assess the effects of the direct stimulation of the PACAP LPB to CeA projection on general locomotor activity, anxiety-like behavior (using a defensive withdrawal test), and mechanical pain sensitivity (using the von Frey test). RESULTS: We found that the CeA, together with other areas, is one of the major downstream projection targets of PACAP neurons originating in the lateral parabrachial nucleus (LPB). In the DREADD experiment, we then found that the selective activation of this neuronal pathway is sufficient to increase both anxiety-like behavior and mechanical pain sensitivity in mice, without affecting general locomotor activity. CONCLUSION: In conclusion, our data suggest that the dysregulation of this circuit may contribute to a variety of anxiety disorders and chronic pain states, and that PACAP may represent an important therapeutic target for the treatment of these conditions.


Subject(s)
Central Amygdaloid Nucleus , Chronic Pain , Mice , Animals , Pituitary Adenylate Cyclase-Activating Polypeptide , Central Amygdaloid Nucleus/metabolism , Hyperalgesia/metabolism , Chronic Pain/metabolism , Anxiety/metabolism , Chronic Disease , Neurons/metabolism
4.
eNeuro ; 9(5)2022.
Article in English | MEDLINE | ID: mdl-36566434

ABSTRACT

Many psychiatric diseases stem from an inability to cope with stressful events, as chronic stressors can precipitate or exacerbate psychopathologies. The neurobiological mechanisms underlying the response to chronic stress and the resulting anxiety states remain poorly understood. Stress neuropeptides in the extended amygdala circuitry mediate the behavioral response to stress, and hyperactivity of these systems has been hypothesized to be responsible for the emergence of persistent negative outcomes and for the pathogenesis of anxiety-related and trauma-related disorders. Pituitary adenylate cyclase-activating polypeptide (PACAP) and its receptor PAC1R are highly expressed within the central amygdala (CeA) and play a key role in stress regulation. Here, we used chronic social defeat stress (CSDS), a clinically relevant model of psychosocial stress that produces robust maladaptive behaviors in rodents. We found that 10 days of CSDS cause a significant increase in PACAP levels selectively in the CeA of rats, as well as an increase in PAC1R mRNA. Using a viral vector strategy, we found that PAC1R knock-down in the CeA attenuates the CSDS-induced body weight loss and prevents the CSDS-induced increase in anxiety-like behavior. Notably, CSDS animals display reduced basal corticosterone (CORT) levels and PAC1R knock-down in CeA further reduce them. Finally, the CeA PAC1R knock-down blocks the increase in corticotropin-releasing factor (CRF) immunoreactivity induced by CSDS in CeA. Our findings support the notion that the persistent activation of the PACAP-PAC1R system in the CeA mediates the behavioral outcomes of chronic psychosocial stress independently of the hypothalamic-pituitary-adrenal axis, perhaps via the recruitment of the CRF system.


Subject(s)
Adaptation, Psychological , Central Amygdaloid Nucleus , Pituitary Adenylate Cyclase-Activating Polypeptide , Social Defeat , Stress, Psychological , Animals , Rats , Central Amygdaloid Nucleus/metabolism , Corticotropin-Releasing Hormone/metabolism , Hypothalamo-Hypophyseal System/metabolism , Pituitary Adenylate Cyclase-Activating Polypeptide/metabolism , Pituitary-Adrenal System/metabolism , Stress, Psychological/metabolism
5.
J Neurosci ; 42(21): 4250-4266, 2022 05 25.
Article in English | MEDLINE | ID: mdl-35504727

ABSTRACT

The Protocadherin-10 (PCDH10) gene is associated with autism spectrum disorder (ASD), obsessive-compulsive disorder (OCD), and major depression (MD). The PCDH10 protein is a homophilic cell adhesion molecule that belongs to the δ2-protocadherin family. PCDH10 is highly expressed in the developing brain, especially in the basolateral nucleus of the amygdala (BLA). However, the role of PCDH10 in vivo has been debatable: one paper reported that a Pcdh10 mutant mouse line showed changes in axonal projections; however, another Pcdh10 mutant mouse line was reported to have failed to detect axonal phenotypes. Therefore, the actual roles of PCDH10 in the brain remain to be elucidated. We established a new Pcdh10 KO mouse line using the CRISPR/Cas9 system, without inserting gene cassettes to avoid nonspecific effects, examined the roles of PCDH10 in the brain, and studied the behavioral consequences of Pcdh10 inactivation. Here, we show that Pcdh10 KO mice do not show defects in axonal development. Instead, we find that Pcdh10 KO mice exhibit impaired development of excitatory synapses in the dorsal BLA. We further demonstrate that male Pcdh10 KO mice exhibit reduced anxiety-related behaviors, impaired fear conditioning, decreased stress-coping responses, and mildly impaired social recognition and communication. These results indicate that PCDH10 plays a critical role in excitatory synapse development, but not axon development, in the dorsal BLA and that PCDH10 regulates anxiety-related, fear-related, and stress-related behaviors. Our results reveal the roles of PCDH10 in the brain and its relationship to relevant psychiatric disorders such as ASD, OCD, and MD.SIGNIFICANCE STATEMENTProtocadherin-10 (PCDH10) encodes a cell adhesion molecule and is implicated in autism spectrum disorder (ASD), obsessive-compulsive disorder (OCD), and major depression (MD). PCDH10 is highly expressed in the basolateral nucleus of the amygdala (BLA). However, the phenotypes of previously published Pcdh10 mutant mice are debatable, and some are possibly because of the nonspecific effects of the LacZ/Neo cassette inserted in the mice. We have generated a new Pcdh10 mutant mouse line without the LacZ/Neo cassette. Using our new mouse line, we reveal the roles of PCDH10 for excitatory synapse development in the BLA. The mutant mice exhibit anxiety-related, fear-related, and stress-related behaviors, which are relevant to ASD, OCD, and MD, suggesting a possible treatment strategy for such psychiatric disorders.


Subject(s)
Autism Spectrum Disorder , Obsessive-Compulsive Disorder , Amygdala/metabolism , Animals , Anxiety/genetics , Anxiety/psychology , Autism Spectrum Disorder/metabolism , Fear/physiology , Humans , Male , Mice , Protocadherins , Synapses/metabolism
6.
Neuropharmacology ; 160: 107761, 2019 12 01.
Article in English | MEDLINE | ID: mdl-31493466

ABSTRACT

Anxiety-related disorders are the most prevalent mental disorders in the world and they are characterized by abnormal responses to stressors. Pituitary adenylate cyclase-activating polypeptide (PACAP) is a neuropeptide highly expressed in the extended amygdala, a brain macrostructure involved in the response to threat that includes the central nucleus of the amygdala (CeA) and the bed nucleus of the stria terminalis (BNST). The aim of this series of experiments was to systematically elucidate the role of the PACAP system of the CeA and BNST under both control, unstressed conditions and after the presentation of a stressor in rats. For this purpose, we used the acoustic startle response (ASR), an unconscious response to sudden acoustic stimuli sensitive to changes in stress which can be used as an operationalization of the hypervigilance present in anxiety- and trauma-related disorders. We found that infusion of PACAP, but not the related peptide vasoactive intestinal peptide (VIP), into either the CeA or the BNST causes a dose-dependent increase in ASR. In addition, while infusion of the antagonist PACAP(6-38) into either the CeA or the BNST does not affect ASR in non-stressed conditions, it prevents the sensitization of ASR induced by an acute footshock stress. Finally, we found that footshock stress induces a significant increase in PACAP, but not VIP, levels in both of these brain areas. Altogether, these data show that the PACAP system of the extended amygdala contributes to stress-induced hyperarousal and suggest it as a potential novel target for the treatment of stress-related disorders.


Subject(s)
Central Amygdaloid Nucleus/drug effects , Pituitary Adenylate Cyclase-Activating Polypeptide/pharmacology , Reflex, Startle/drug effects , Septal Nuclei/drug effects , Stress, Psychological , Animals , Anxiety/metabolism , Anxiety/pathology , Behavior, Animal/drug effects , Central Amygdaloid Nucleus/metabolism , Male , Pituitary Adenylate Cyclase-Activating Polypeptide/administration & dosage , Rats , Rats, Wistar , Septal Nuclei/metabolism , Vasoactive Intestinal Peptide/metabolism
7.
Mol Inform ; 38(6): e1800171, 2019 06.
Article in English | MEDLINE | ID: mdl-30861311

ABSTRACT

Molecular acid/base properties have a significant influence on membrane permeation, metabolism, absorption, and affinity for biological targets. In particular, ionizable groups are critical in the strength of target-molecule interactions, pharmacokinetics, and toxicity. In this study, we estimated the acid/base properties of the food chemicals from FooDB, a public compound collection with more than 22,000 compounds. It was found that the food chemicals have 40.9 % of neutral compounds, which is twice as many as that found in approved drugs. The most common functional groups among the acid groups in the food chemicals were phenols (16.1 %), phosphates (17.3 %), and carboxylates (17.3 %) while the single-base-containing compounds were of less interest as they accounted for just 5.5 %. To the best of our knowledge, this is the first systematic acid/base profiling of food chemicals and it is part of a continued effort to profile food chemicals for their broad interest in several areas such as nutrition and the food industry in general.


Subject(s)
Carboxylic Acids/analysis , Databases, Pharmaceutical , Food Contamination/analysis , Phenols/analysis , Phosphates/analysis , Hydrogen-Ion Concentration
8.
F1000Res ; 72018.
Article in English | MEDLINE | ID: mdl-30135721

ABSTRACT

Background: Food chemicals are a cornerstone in the food industry. However, its chemical diversity has been explored on a limited basis, for instance, previous analysis of food-related databases were done up to 2,200 molecules. The goal of this work was to quantify the chemical diversity of chemical compounds stored in FooDB, a database with nearly 24,000 food chemicals. Methods: The visual representation of the chemical space of FooDB was done with ChemMaps, a novel approach based on the concept of chemical satellites. The large food chemical database was profiled based on physicochemical properties, molecular complexity and scaffold content. The global diversity of FoodDB was characterized using Consensus Diversity Plots. Results: It was found that compounds in FooDB are very diverse in terms of properties and structure, with a large structural complexity. It was also found that one third of the food chemicals are acyclic molecules and ring-containing molecules are mostly monocyclic, with several scaffolds common to natural products in other databases. Conclusions: To the best of our knowledge, this is the first analysis of the chemical diversity and complexity of FooDB. This study represents a step further to the emerging field of "Food Informatics". Future study should compare directly the chemical structures of the molecules in FooDB with other compound databases, for instance, drug-like databases and natural products collections.


Subject(s)
Databases, Pharmaceutical , Food , Chemical Phenomena
9.
Psychopharmacology (Berl) ; 232(20): 3821-31, 2015 Oct.
Article in English | MEDLINE | ID: mdl-26264905

ABSTRACT

BACKGROUND: Major depressive disorder (MDD) is a chronic, life-threatening psychiatric condition characterized by depressed mood, psychomotor alterations, and a markedly diminished interest or pleasure in most activities known as anhedonia. Available pharmacotherapies have limited success and the need for new strategies is clear. Recent studies attribute a major role to the pituitary adenylate cyclase-activating polypeptide (PACAP) system in mediating the response to stress. PACAP knockout mice display profound alterations in depressive-like behaviors, and genetic association studies have demonstrated that genetic variants of the PACAP gene are associated with MDD. However, the effects of PACAP administration on depressive-like behaviors in rodents have not yet been systematically examined. OBJECTIVES: The present study investigated the effects of central administration of PACAP in rats on depressive-like behaviors, using well-established animal models that represent some of the endophenotypes of depression. METHODS: We used intracranial self-stimulation (ICSS) to assess the brain reward function, saccharin preference test to assess anhedonia, social interaction to assess social withdrawal, and forced swim test (FST) to assess behavioral despair. RESULTS: PACAP raised the current threshold for ICSS, elevation blocked by the PACAP antagonist PACAP(6-38). PACAP reduced the preference for a sweet saccharin solution and reduced the time the rats spent interacting with a novel animal. Interestingly, PACAP administration did not affect immobility in the FST. CONCLUSIONS: Our results demonstrate a role for the central PACAP/PAC1R system in the regulation of depressive-like behaviors and suggest that hyperactivity of the PACAP/PAC1R system may contribute to the pathophysiology of depression, particularly the associated anhedonic symptomatology and social dysfunction.


Subject(s)
Depression/chemically induced , Depression/metabolism , Phenotype , Pituitary Adenylate Cyclase-Activating Polypeptide/administration & dosage , Pituitary Adenylate Cyclase-Activating Polypeptide/toxicity , Adenylyl Cyclases/metabolism , Animals , Depression/psychology , Dose-Response Relationship, Drug , Infusions, Intraventricular , Male , Rats , Rats, Wistar
10.
Surg Neurol Int ; 5: 70, 2014.
Article in English | MEDLINE | ID: mdl-24991473

ABSTRACT

BACKGROUND: Although the added value of increasing extent of glioblastoma resection is still debated, multiple technologies can assist neurosurgeons in attempting to achieve this goal. Intraoperative magnetic resonance imaging (iMRI) might be helpful in this context, but to date only one randomized trial exists. METHODS: We included 14 adults with a supratentorial tumor suspect for glioblastoma and an indication for gross total resection in this randomized controlled trial of which the interim analysis is presented here. Participants were assigned to either ultra-low-field strength iMRI-guided surgery (0.15 Tesla) or to conventional neuronavigation-guided surgery (cNN). Primary endpoint was residual tumor volume (RTV) percentage. Secondary endpoints were clinical performance, health-related quality of life (HRQOL) and survival. RESULTS: Median RTV in the cNN group is 6.5% with an interquartile range of 2.5-14.75%. Median RTV in the iMRI group is 13% with an interquartile range of 3.75-27.75%. A Mann-Whitney test showed no statistically significant difference between these groups (P =0.28). Median survival in the cNN group is 472 days, with an interquartile range of 244-619 days. Median survival in the iMRI group is 396 days, with an interquartile range of 191-599 days (P =0.81). Clinical performance did not differ either. For HRQOL only descriptive statistics were applied due to a limited sample size. CONCLUSION: This interim analysis of a randomized trial on iMRI-guided glioblastoma resection compared with cNN-guided glioblastoma resection does not show an advantage with respect to extent of resection, clinical performance, and survival for the iMRI group. Ultra-low-field strength iMRI does not seem to be cost-effective compared with cNN, although the lack of a valid endpoint for neurosurgical studies evaluating extent of glioblastoma resection is a limitation of our study and previous volumetry-based studies on this topic.

11.
Neuropsychopharmacology ; 37(7): 1620-31, 2012 Jun.
Article in English | MEDLINE | ID: mdl-22395732

ABSTRACT

Anorexia nervosa (AN) is an eating disorder characterized by extreme hypophagia, hyperactivity, and fear of weight gain. No approved pharmacological treatments exist for AN despite high mortality rates. The activity-based anorexia (ABA) phenomenon models aspects of AN in rodents, including progressive weight loss, reduced food intake, and hyperactivity. First, we optimized the ABA paradigm for mice. We compared mouse strains (Balb/cJ, A/J) for susceptibility with ABA, and evaluated the effects of different food access durations (2, 4, 6, 8, and 10 h) on ABA parameters. Balb/cJ mice exhibited significantly shorter survival time (days until 25% bodyweight loss) in the ABA paradigm compared with A/J mice. Furthermore, 6 h of food access reduced survival in mice housed with wheels without reducing survival in mice housed without wheels. We then evaluated the effects of chronic treatment with fluoxetine (4 weeks) or subchronic treatment with olanzapine (OLZ) (1 week) on ABA in BALB/cJ mice. OLZ (12 mg/kg/day) significantly increased survival and reduced food anticipatory activity (FAA). However, OLZ did not alter food intake or running wheel activity during ad-lib feeding (baseline) or restriction conditions, or in mice housed without wheels. Fluoxetine (18 mg/kg/day) increased food intake and reduced FAA, but did not alter survival. Here, we report for the first time that OLZ, but not fluoxetine, reduces ABA in mice. Our findings indicate further need for clinical investigations into the effects of OLZ, but not selective serotonin reuptake inhibitors, on core features of AN.


Subject(s)
Anorexia/drug therapy , Benzodiazepines/therapeutic use , Fluoxetine/therapeutic use , Motor Activity/drug effects , Selective Serotonin Reuptake Inhibitors/therapeutic use , Animals , Anorexia/mortality , Benzodiazepines/pharmacology , Body Weight/drug effects , Disease Models, Animal , Dose-Response Relationship, Drug , Eating/drug effects , Female , Fluoxetine/pharmacology , Mice , Olanzapine , Running , Selective Serotonin Reuptake Inhibitors/pharmacology , Survival Rate
12.
Surg Neurol Int ; 3: 158, 2012.
Article in English | MEDLINE | ID: mdl-23372974

ABSTRACT

OBJECT: Glioblastoma is a highly malignant brain tumor, for which standard treatment consists of surgery, radiotherapy, and chemotherapy. Increasing extent of tumor resection (EOTR) is associated with prolonged survival. Intraoperative magnetic resonance imaging (iMRI) is used to increase EOTR, based on contrast enhanced MR images. The correlation between intraoperative contrast enhancement and tumor has not been studied systematically. METHODS: For this prospective cohort study, we recruited 10 patients with a supratentorial brain tumor suspect for a glioblastoma. After initial resection, a 0.15 Tesla iMRI scan was made and neuronavigation-guided biopsies were taken from the border of the resection cavity. Scores for gadolinium-based contrast enhancement on iMRI and for tissue characteristics in histological slides of the biopsies were used to calculate correlations (expressed in Kendall's tau). RESULTS: A total of 39 biopsy samples was available for further analysis. Contrast enhancement was significantly correlated with World Health Organization (WHO) grade (tau 0.50), vascular changes (tau 0.53), necrosis (tau 0.49), and increased cellularity (tau 0.26). Specificity of enhancement patterns scored as "thick linear" and "tumor-like" for detection of (high grade) tumor was 1, but decreased to circa 0.75 if "thin linear" enhancement was included. Sensitivity for both enhancement patterns varied around 0.39-0.48 and 0.61-0.70, respectively. CONCLUSIONS: Presence of intraoperative contrast enhancement is a good predictor for presence of tumor, but absence of contrast enhancement is a bad predictor for absence of tumor. The use of gadolinium-based contrast enhancement on iMRI to maximize glioblastoma resection should be evaluated against other methods to increase resection, like new contrast agents, other imaging modalities, and "functional neurooncology" - an approach to achieve surgical resection guided by functional rather than oncological-anatomical boundaries.

13.
Lancet Oncol ; 12(11): 1062-70, 2011 Oct.
Article in English | MEDLINE | ID: mdl-21868286

ABSTRACT

We did a systematic review to address the added value of intraoperative MRI (iMRI)-guided resection of glioblastoma multiforme compared with conventional neuronavigation-guided resection, with respect to extent of tumour resection (EOTR), quality of life, and survival. 12 non-randomised cohort studies matched all selection criteria and were used for qualitative synthesis. Most of the studies included descriptive statistics of patient populations of mixed pathology, and iMRI systems of varying field strengths between 0·15 and 1·5 Tesla. Most studies provided information on EOTR, but did not always mention how iMRI affected the surgical strategy. Only a few studies included information on quality of life or survival for subpopulations with glioblastoma multiforme or high-grade glioma. Several limitations and sources of bias were apparent, which affected the conclusions drawn and might have led to overestimation of the added value of iMRI-guided surgery for resection of glioblastoma multiforme. Based on the available literature, there is, at best, level 2 evidence that iMRI-guided surgery is more effective than conventional neuronavigation-guided surgery in increasing EOTR, enhancing quality of life, or prolonging survival after resection of glioblastoma multiforme.


Subject(s)
Brain Neoplasms/surgery , Glioblastoma/surgery , Magnetic Resonance Imaging, Interventional , Microsurgery , Neurosurgical Procedures , Surgery, Computer-Assisted , Brain Neoplasms/diagnosis , Brain Neoplasms/mortality , Brain Neoplasms/pathology , Evidence-Based Medicine , Glioblastoma/diagnosis , Glioblastoma/mortality , Glioblastoma/pathology , Humans , Microsurgery/adverse effects , Microsurgery/mortality , Neurosurgical Procedures/adverse effects , Neurosurgical Procedures/mortality , Quality of Life , Surgery, Computer-Assisted/adverse effects , Surgery, Computer-Assisted/mortality , Survival Rate , Time Factors , Treatment Outcome
14.
Psychopharmacology (Berl) ; 213(2-3): 509-20, 2011 Feb.
Article in English | MEDLINE | ID: mdl-21181117

ABSTRACT

RATIONALE: The antidepressant response exhibits a characteristic delay. BALB/cJ mice respond to chronic, but not subchronic, treatment with selective serotonin reuptake inhibitors (SSRIs), providing a model of antidepressant onset. Identification of other mouse strains exhibiting this phenotype will provide additional tools for studying mechanisms of the antidepressant response. OBJECTIVES: We aimed to identify inbred mouse strains that respond to chronic, but not subchronic, SSRI treatment in the forced swim test (FST). We also assessed whether response correlated with genotype at the functional C1473G polymorphism in tryptophan hydroxylase-2 (Tph2). METHODS: BALB/cJ, three closely related strains (BALB/cByJ, SEA/GnJ, A/J), and four distantly related strains (C57BL/6J, C57BL/10J, CAST/EiJ, SM/J) received the SSRI citalopram (0-30 mg/kg/day in drinking water) for ~4 weeks and were assessed for locomotion and FST behavior. Citalopram-responsive strains were assessed identically following ~1 week of treatment. C1473G genotypes were determined. RESULTS: BALB/cJ and related strains carried the 1473G allele and responded to chronic citalopram treatment in the FST. BALB/cJ, BALB/cByJ, and SEA/GnJ mice showed either no response or an attenuated response to subchronic treatment. Distantly related strains carried the 1473C allele and showed no response to citalopram. No relationship was found between the antidepressant response and baseline immobility or locomotion. CONCLUSIONS: BALB/cJ and related strains exhibit an antidepressant response to chronic SSRI treatment that emerges over time and is likely a heritable trait. This antidepressant response is associated with carrying the 1473G allele in Tph2. In conclusion, BALB/cJ and related strains provide valuable models for studying the therapeutic mechanisms of SSRIs.


Subject(s)
Antidepressive Agents, Second-Generation/pharmacology , Citalopram/pharmacology , Selective Serotonin Reuptake Inhibitors/pharmacology , Tryptophan Hydroxylase/genetics , Animals , Antidepressive Agents, Second-Generation/administration & dosage , Behavior, Animal/drug effects , Citalopram/administration & dosage , Depression/drug therapy , Depression/physiopathology , Disease Models, Animal , Drug Administration Schedule , Female , Locomotion/drug effects , Mice , Mice, Inbred BALB C , Mice, Inbred C57BL , Mice, Inbred Strains , Selective Serotonin Reuptake Inhibitors/administration & dosage , Species Specificity , Swimming , Time Factors
15.
J Neurosurg Pediatr ; 4(6): 588-91, 2009 Dec.
Article in English | MEDLINE | ID: mdl-19951050

ABSTRACT

Juvenile xanthogranuloma (JXG) is a rare histiocytic disorder primarily observed during the first 2 years of life. Most patients present with a solitary cutaneous lesion; however, others present with extracutaneous manifestations or even with systemic involvement. The authors describe a 2-month-old boy in whom was diagnosed a unifocal extracutaneous JXG involving the temporal bone. Unlike 3 other cases of solitary JXGs of the temporal bone in the literature, the present case involved destruction of the dura mater and leptomeningeal enhancement surrounding the entire temporal lobe. The lesion did not regress after an initial biopsy procedure and had to be removed more radically because of progressive mass effect on the brain. The child recently underwent a reconstructive skull procedure and is doing well almost 2 years postoperatively without evidence of disease. This case demonstrates that even in instances of extensive disease a favorable outcome is possible without chemotherapy.


Subject(s)
Bone Diseases/surgery , Dura Mater/surgery , Muscular Diseases/surgery , Temporal Bone , Temporal Muscle , Xanthogranuloma, Juvenile/surgery , Bone Diseases/diagnosis , Dura Mater/pathology , Humans , Infant , Magnetic Resonance Imaging , Male , Muscular Diseases/diagnosis , Plastic Surgery Procedures , Reoperation , Temporal Bone/diagnostic imaging , Temporal Bone/pathology , Temporal Bone/surgery , Temporal Muscle/diagnostic imaging , Temporal Muscle/pathology , Temporal Muscle/surgery , Tomography, X-Ray Computed , Xanthogranuloma, Juvenile/diagnosis
17.
Brain Res ; 1035(1): 86-93, 2005 Feb 21.
Article in English | MEDLINE | ID: mdl-15713280

ABSTRACT

Diabetes mellitus can lead to functional and structural deficits in both the peripheral and central nervous system. The pathogenesis of these deficits is multifactorial, probably involving, among others, microvascular dysfunction and alterations in intracellular calcium homeostasis. The present study examined the effects of treatment with the Ca2+ antagonist nimodipine (20 mg/kg, intraperitoneal injection, every 48 h) on functional deficits in the peripheral and central nervous system in streptozotocin-diabetic rats. In a prevention experiment, treatment was initiated immediately after diabetes induction and continued for 10 weeks. In a reversal experiment, treatment was initiated 16 weeks after diabetes induction and continued for 12 weeks. Sciatic nerve motor and sensory conduction velocity, brainstem auditory-evoked potentials, and visual-evoked potentials were measured in control, untreated, and nimodipine-treated diabetic rats. In addition, long-term potentiation, a form of synaptic plasticity used as a model for learning and memory at the cellular level, was examined in hippocampal slices. Nimodipine treatment partially prevented deficits in nerve conduction velocity and hippocampal long-term potentiation in diabetic rats. However, nimodipine intervention treatment was unable to reverse established deficits in nerve conduction velocity, evoked potential latencies, or long-term potentiation. It is concluded that nimodipine can partially prevent early functional deficits in the peripheral and central nervous system of streptozotocin-diabetic rats but is unable to reverse late deficits.


Subject(s)
Calcium Channel Blockers/pharmacology , Central Nervous System/drug effects , Diabetes Mellitus, Experimental/physiopathology , Nimodipine/pharmacology , Peripheral Nervous System/drug effects , Analysis of Variance , Animals , Blood Glucose/physiology , Body Weight/drug effects , Brain Stem/drug effects , Brain Stem/physiopathology , Central Nervous System/physiopathology , Diabetes Mellitus, Experimental/chemically induced , Drug Administration Schedule , Electric Stimulation/methods , Evoked Potentials, Visual/drug effects , Evoked Potentials, Visual/physiology , Hippocampus/drug effects , Hippocampus/physiology , In Vitro Techniques , Long-Term Potentiation/drug effects , Long-Term Potentiation/physiology , Long-Term Potentiation/radiation effects , Male , Membrane Potentials/drug effects , Membrane Potentials/physiology , Neural Conduction/drug effects , Peripheral Nervous System/physiopathology , Rats , Rats, Wistar , Reaction Time/drug effects , Reaction Time/physiology , Sciatic Nerve/drug effects , Sciatic Nerve/physiopathology , Streptozocin , Time Factors
18.
Eur J Pharmacol ; 462(1-3): 179-83, 2003 Feb 21.
Article in English | MEDLINE | ID: mdl-12591111

ABSTRACT

The neurotrophic and neuroprotective potential of the alpha-melanocyte-stimulating hormone (alpha-MSH) analog cyclo-[Ac-Nle(4),Asp(5),D-Phe(7),Lys(10)]alpha-MSH-(4-10) amide (melanotan-II), a potent melanocortin receptor agonist, was investigated. The sciatic nerve crush model was used as a paradigm to investigate the neurotrophic properties of melanotan-II. Melanotan-II significantly enhanced the recovery of sensory function following a crush lesion of the sciatic nerve in the rat at a dose of 20 microg kg(-1) per 48 h, s.c., but not at a dose of 2 or 50 microg kg(-1). In addition, we observed that melanotan-II also possesses neuroprotective properties, as it partially protected the nerve from a toxic neuropathy induced by cisplatin. Thus, the present data for the first time demonstrate the effectiveness of the potent alpha-MSH analog melanotan-II in nerve regeneration and neuroprotection.


Subject(s)
Nerve Regeneration/drug effects , Neuroprotective Agents/pharmacology , Peptides, Cyclic/pharmacology , Peripheral Nervous System/physiology , Receptors, Corticotropin/agonists , alpha-MSH/analogs & derivatives , alpha-MSH/pharmacology , Animals , Cisplatin/administration & dosage , Foot/innervation , Male , Neural Conduction/drug effects , Rats , Rats, Wistar , Receptors, Melanocortin , Reflex/drug effects , Sciatic Nerve/injuries , Sciatic Nerve/physiology , Sciatic Neuropathy/etiology , Sciatic Neuropathy/physiopathology , Sciatic Neuropathy/prevention & control
19.
Eur J Pharmacol ; 447(2-3): 201-9, 2002 Jul 05.
Article in English | MEDLINE | ID: mdl-12151012

ABSTRACT

The Ca(2+) hypothesis of brain ageing and dementia may account for part of the available data on the pathogenesis of dementia and certain neurodegenerative disorders. The hypothesis proposes that disturbances in the homeostasis of neuronal cytosolic free Ca(2+) are part of a final common pathway, ultimately leading to neuronal dysfunction and cell death. The hypothesis also proposes that a small change in cytosolic free Ca(2+) sustained over a long period of time will result in similar damage as a large change over a short period. Diabetes mellitus is associated with neurological complications in the peripheral and central nervous system, as reflected in peripheral neuropathy, modest cognitive impairments and an increased risk of dementia. In animal models of diabetes, learning impairments are associated with alterations in Ca(2+) -dependent forms of hippocampal synaptic plasticity. Disturbances in the homeostasis of cytosolic free Ca(2+) may present a final common pathway in the multifactorial pathogenesis of neurological complications of diabetes, which involves vascular changes, oxidative stress, and non-enzymatic protein glycation. In line with the Ca(2+) hypothesis of neurodegenerative disorders, a prolonged, small increase in basal cytosolic Ca(2+) levels indeed exists in sensory neurones of diabetic animals. In addition, Ca(2+) dynamics are affected. Ca(2+) channel blockers, such as nimodipine, have been shown to improve experimental peripheral neuropathy, through a vascular mechanism, possibly in combination with direct neuronal effects. Preliminary studies indicate that nimodipine may also improve Ca(2+)-dependent forms of synaptic plasticity in the hippocampus of diabetic rats.


Subject(s)
Calcium/metabolism , Diabetes Mellitus/etiology , Neurons/metabolism , Aging/metabolism , Animals , Calcium Channel Blockers/therapeutic use , Diabetes Mellitus/drug therapy , Diabetes Mellitus/metabolism , Diabetic Neuropathies/drug therapy , Diabetic Neuropathies/etiology , Homeostasis , Humans , Neuronal Plasticity
20.
Neurochirurgie ; 33(1): 84-6, 1987.
Article in French | MEDLINE | ID: mdl-3550505

ABSTRACT

To prevent crusty rhinitis responsible for necrosis and sequestration of bone grafts used for anterior reconstruction following the extensive resection of ethmoido-frontal neoplasms, the authors propose lining the endocranial surface of these grafts by pericranium with a temporalis muscle based pedicle. The endonasal surface is covered by a pedicle galea flap taken from the frontal scalp and introduced via a para-latero-nasal E.N.T. approach.


Subject(s)
Bone Transplantation , Skull Neoplasms/surgery , Surgical Flaps , Ethmoid Bone/surgery , Frontal Bone/surgery , Humans , Postoperative Complications/prevention & control , Rhinitis/prevention & control
SELECTION OF CITATIONS
SEARCH DETAIL
...